Physician profile
Iris Looi
NPI 1326412495
$10,800.59
in general payments reported to CMS, 2019-2025
30 companies · $2,628 in 2025
The $2,628 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,795 · 2022: $2,100 · 2023: $2,226 · 2024: $2,051 · 2025: $2,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,405 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,405.22 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,728.97 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,156.38 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Incyte Corporation | $1,106.19 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $982.30 | 2021-2025 | |
| Pfizer INC. | $949.57 | 2021-2025 | |
| Journey Medical Corporation | $580.23 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $549.63 | 2021-2025 | Cabtreo, Jublia |
| Amgen INC. | $543.65 | 2022-2025 | Otezla, Otezla |
| Merz North America, INC. | $482.47 | 2021-2023 | Xeomin |
| Leo Pharma INC. | $363.13 | 2021-2025 | Adbry, Anzupgo |
| Allergan, INC. | $346.70 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $337.42 | 2021-2025 | Winlevi, Absorica Ld |
| Almirall LLC | $291.78 | 2021-2024 | Klisyri, Seysara |
| Regeneron Healthcare Solutions, INC. | $200.30 | 2022-2025 | Libtayo, Dupixent |
| Vyne Pharmaceuticals INC. | $195.69 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $177.58 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $146.52 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $124.47 | 2024-2025 | Taltz, Ebglyss |
| Ucb, INC. | $99.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $70.53 | 2022-2024 | |
| Organon LLC | $69.97 | 2025 | Vtama |
| Biofrontera INC. | $59.76 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $53.42 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $50.18 | 2024-2025 | Zoryve |
| Epi Health, LLC | $34.64 | 2022 | |
| Dermavant Sciences, INC. | $24.75 | 2024 | Vtama |
| Dermira, INC. | $21.85 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.07 | 2025 | Clear+Brilliant |
| Janssen Biotech, INC. | $17.53 | 2025 | Tremfya |
| Mission Pharmacal Company | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Looi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.